Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

bispecific antibody JNJ-70218902

A T-cell redirecting agent and bispecific antibody targeting an as of yet undisclosed tumor-associated antigen (TAA) expressed on tumor cells and the CD3 receptor complex expressed on T cells, with potential immunomodulating and antineoplastic activities. Upon administration, bispecific antibody JNJ-70218902 binds to both CD3 on T cells and a TAA expressed on tumor cells. The resulting cross-linkage activates and redirects T cells to the TAA-expressing tumor cells. This results in T-cell-mediated lysis of tumor cells.
Synonym:T-cell-redirecting agent JNJ-70218902
Code name:JNJ 70218902
JNJ-70218902
JNJ70218902
Search NCI's Drug Dictionary